From Data to Movement: The Breakthrough Helping Paralyzed Patients Walk Again
16 janv. 2025 08h00 HE
|
SciChart
From Data to Movement: NeuroRestore, powered by SciChart, combines spinal stimulation with real-time data to help paralyzed patients walk again.
From Data to Movement: The Breakthrough Helping Paralyzed Patients Walk Again
16 janv. 2025 04h04 HE
|
SciChart
From Data to Movement: NeuroRestore, powered by SciChart, combines spinal stimulation with real-time data to help paralyzed patients walk again.
Alliance for Decision Education Launches Season 5 of The Decision Education Podcast
15 janv. 2025 10h07 HE
|
Alliance for Decision Education
The Alliance for Decision Education announces Season 5 of The Decision Education Podcast, featuring renowned experts and host Annie Duke.
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
10 janv. 2025 07h00 HE
|
Arvinas Inc.
– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line Phase 3 combination trial will...
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
08 janv. 2025 13h30 HE
|
Institute of Molecular and Clinical Ophthalmology Basel (IOB)
Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study,...
Firefly Neuroscience Closes on Financing of up to $12.4 Million
31 déc. 2024 09h00 HE
|
Firefly Neuroscience, Inc.
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
30 déc. 2024 00h45 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA...
Precision Neuroscience Raises $102 Million to Advance AI-Powered Brain Implant
16 déc. 2024 07h00 HE
|
Precision Neuroscience
The raise brings Precision’s total funding to $155 million, solidifying its position as a leader in the brain–computer interface industry.Investors include General Equity Holdings, B Capital, Stanley...
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
10 déc. 2024 09h05 HE
|
Arvinas Inc.
– Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6...
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society
06 déc. 2024 12h00 HE
|
Neurona Therapeutics
Neurona Therapeutics Presents Positive Clinical Update:
New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meet